Five-year open-label extension study of safety and efficacy of etanercept in children and adolescents with moderate to severe plaque psoriasis

被引：0

作者：

Paller, Amy S. ^{[1
]}

Siegfried, Elaine C. ^{[2
,3
]}

Pariser, David M. ^{[4
]}

Rice, Kara Creamer ^{[5
]}

Trivedi, Mona ^{[5
]}

Iles, Jan ^{[5
]}

Collier, David H. ^{[5
]}

Kricorian, Greg ^{[5
]}

Langley, Richard G. ^{[6
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[2] Cardinal Glennon Childrens Hosp, St Louis, MO USA

[3] St Louis Univ, St Louis, MO 63103 USA

[4] Eastern Virginia Med Sch, Norfolk, VA 23501 USA

[5] Amgen Inc, Thousand Oaks, CA 91320 USA

[6] Dalhousie Univ, Halifax, NS, Canada

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

2607

引用

页码：AB251 / AB251

页数：1

共 50 条

[1] Safety and efficacy of etanercept treatment in children and adolescents with plaque psoriasis: 96-week results of open-label extension study
Paller, Amy
Pariser, David
Siegfried, Elaine
Kricorian, Gregory
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB11 - AB11
[2] Efficacy and safety of adalimumab in a 120-week open-label extension study in patients with moderate to severe chronic plaque psoriasis
Papp, Kim
Leonardi, Craig
Gordon, Kenneth
Frevert, Lisa
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB193 - AB193
[3] Efficacy and safety of etanercept in moderate to severe plaque psoriasis
Tunca, M.
Koc, E.
Akar, A.
Kurumlu, Z.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 : 53 - 53
[4] Tofacitinib in patients with moderate to severe chronic plaque psoriasis: 2-year efficacy and safety in an open-label long-term extension study
Paul, Carle
Langley, Richard G.
Valenzuela, Fernando
Cather, Jennifer
Gardner, Annie
Proulx, James
Tan, Huaming
Wolk, Robert
Kaur, Mandeep
Rottinghaus, Scott
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB278 - AB278
[5] Efficacy and safety of briakinumab for treatment of moderate to severe psoriasis in patients previously receiving etanercept: Results from an open-label extension
Strober, Bruce
Leonardi, Craig
Williams, David A.
Olds, Michele
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB191 - AB191
[6] Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
Valenzuela, F.
Korman, N. J.
Bissonnette, R.
Bakos, N.
Tsai, T. -F.
Harper, M. K.
Ports, W. C.
Tan, H.
Tallman, A.
Valdez, H.
Gardner, A. C.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 853 - 862
[7] An open-label extension study evaluating the efficacy and safety of oral tazarotene in plaque psoriasis
Papp, KA
Beddingfield, F
Manrow, S
Walker, PS
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P153 - P153
[8] A long-term, open-label study of the safety and efficacy of oral tazarotene in moderate to very severe plaque psoriasis
Menter, A
Lew-Kaya, D
Beddingfield, F
Walker, PS
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P2 - P2
[9] Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast
Bagel, Jerry
Samad, Ahmed S.
Stolshek, Bradley S.
Aras, Girish A.
Chung, James B.
Kricorian, Gregory
Kircik, Leon H.
[J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (10) : 1078 - 1082
[10] A 12-week phase 3 study of efficacy and safety of etanercept therapy in children and adolescents with moderate to severe plaque psoriasis
Paller, Amy
Siegfried, Elaine
Langley, Richard
Gottlieb, Alice
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB195 - AB195

← 1 2 3 4 5 →